NEUROCRINE BIOSCIENCES INC's ticker is and the CUSIP is 64125CAD1. A total of 52 filers reported holding NEUROCRINE BIOSCIENCES INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $5,019,203 | -19.2% | 3,168,000 | -28.5% | 0.05% | -22.4% |
Q3 2022 | $6,210,000 | -1.4% | 4,428,000 | -6.8% | 0.07% | +6.3% |
Q2 2022 | $6,298,000 | -63.8% | 4,750,000 | -64.1% | 0.06% | -62.9% |
Q1 2022 | $17,384,000 | +4.8% | 13,230,000 | 0.0% | 0.17% | +9.7% |
Q4 2021 | $16,595,000 | -5.6% | 13,230,000 | 0.0% | 0.16% | +2.0% |
Q3 2021 | $17,584,000 | +0.2% | 13,230,000 | 0.0% | 0.15% | +13.4% |
Q2 2021 | $17,541,000 | -16.3% | 13,230,000 | -14.7% | 0.13% | -24.3% |
Q1 2021 | $20,948,000 | -52.9% | 15,508,000 | -51.8% | 0.18% | -55.2% |
Q3 2020 | $44,437,000 | +4.3% | 32,181,000 | +25.7% | 0.40% | -7.7% |
Q2 2020 | $42,625,000 | +81.6% | 25,595,000 | +40.2% | 0.43% | +25.5% |
Q1 2020 | $23,476,000 | +7.6% | 18,250,000 | +42.8% | 0.34% | +34.3% |
Q3 2018 | $21,819,000 | +177.4% | 12,776,000 | +135.2% | 0.25% | +149.0% |
Q2 2018 | $7,866,000 | – | 5,431,000 | – | 0.10% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TENOR CAPITAL MANAGEMENT Co., L.P. | 45,447,000 | $60,497,000 | 1.31% |
SHENKMAN CAPITAL MANAGEMENT INC | 4,366,000 | $5,924,000 | 0.54% |
Aequim Alternative Investments LP | 7,609,000 | $10,088,000 | 0.43% |
MACKAY SHIELDS LLC | 27,806,000 | $37,405,000 | 0.35% |
Weiss Asset Management LP | 10,000,000 | $13,290,000 | 0.33% |
WOLVERINE ASSET MANAGEMENT LLC | 13,230,000 | $17,541,000 | 0.13% |
Polar Asset Management Partners Inc. | 7,500,000 | $9,942,000 | 0.10% |
LORD, ABBETT & CO. LLC | 22,141,000 | $29,732,000 | 0.07% |
Calamos Advisors LLC | 7,500,000 | $9,967,000 | 0.05% |
D. E. Shaw & Co., Inc. | 39,270,000 | $52,046,000 | 0.04% |